Search Results - "Larroquette, Mathieu"

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression by Vanhersecke, Lucile, Brunet, Maxime, Guégan, Jean-Philippe, Rey, Christophe, Bougouin, Antoine, Cousin, Sophie, Moulec, Sylvestre Le, Besse, Benjamin, Loriot, Yohann, Larroquette, Mathieu, Soubeyran, Isabelle, Toulmonde, Maud, Roubaud, Guilhem, Pernot, Simon, Cabart, Mathilde, Chomy, François, Lefevre, Corentin, Bourcier, Kevin, Kind, Michèle, Giglioli, Ilenia, Sautès-Fridman, Catherine, Velasco, Valérie, Courgeon, Félicie, Oflazoglu, Ezoglin, Savina, Ariel, Marabelle, Aurélien, Soria, Jean-Charles, Bellera, Carine, Sofeu, Casimir, Bessede, Alban, Fridman, Wolf H, Loarer, François Le, Italiano, Antoine

“…Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has…”
Get full text

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study by Ladouceur, Alexandra, Barnetche, Thomas, Mouterde, Gael, Tison, Alice, Bitoun, Samuel, Prey, Sorilla, Dutriaux, Caroline, Gerard, Emilie, Pham-Ledard, Anne, Beylot-Barry, Marie, Zysman, Maeva, Veillon, Rémi, Domblides, Charlotte, Daste, Amaury, Gross-Goupil, Marine, Sionneau, Baptiste, Lefort, Felix, Larroquette, Mathieu, Richez, Christophe, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Kostine, Marie

“…ObjectiveAnother course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse…”
Get full text

FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib by Gibson, Nyere, Larroquette, Mathieu, Domblides, Charlotte, Lefort, Felix, Daste, Amaury

Get full text

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed? by Peyraud, Florent, Larroquette, Mathieu, Ravaud, Alain, Gross-Goupil, Marine

“…Adjuvant therapy with antiangiogenic agents in locoregional renal cell carcinoma did not translate into a sufficient benefit and highlight the crucial role of…”
Get full text

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial by Gross-Goupil, Marine, Lefort, Felix, Larroquette, Mathieu, Asselineau, Julien, Frison, Eric, Albiges, Laurence, Ravaud, Alain

“…TPS487 Background: Treatment of mRCC consists of combination of either Immune Checkpoint Inhibitor (ICI)-Tyrosine Kinase Inhibitor (TKI) for all IMDC prognosis…”
Get full text

Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review by Larroquette, Mathieu, Domblides, Charlotte, Lefort, Félix, Lasserre, Matthieu, Quivy, Amandine, Sionneau, Baptiste, Bertolaso, Pauline, Gross-Goupil, Marine, Ravaud, Alain, Daste, Amaury

“…The use of immune checkpoint inhibitors (ICIs), especially anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), has changed…”
Get full text

Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives by Larroquette, Mathieu, Peyraud, Florent, Domblides, Charlotte, Lefort, Félix, Bernhard, Jean-Christophe, Ravaud, Alain, Gross-Goupil, Marine

“…•While approximately 70% of cases of renal cell carcinoma (RCC) are diagnosed at non-metastatic stage, effective adjuvant treatments are urgently needed to…”
Get full text

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d’Etude des Tumeurs Uro-Genitales) study by Carneiro, Florian, Vinceneux, Armelle, Larroquette, Mathieu, Rony, Maelle, Carril, Lucia, Laguerre, Brigitte, Blazevic, Ilfad, Barthelemy, Philippe, Teyssonneau, Diego, Goujon, Morgan, Linassier, Claude, Thiery-Vuillemin, Antoine, Roubaud, Guilhem, Mourey, Loic, Albiges, Laurence, Gravis, Gwenaelle, Gross-Goupil, Marine, Cancel, Mathilde

“…391 Background: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a…”
Get full text

Atypical presentation of a central nervous system aspergillosis in a peripheral T cell lymphoma patient by Larroquette, Mathieu, Issa, Nahéma, Gabriel, Frédéric, Camou, Fabrice

Get full text

Which place for avelumab in the management of urothelial carcinoma? by Larroquette, Mathieu, Gross-Goupil, Marine, Daste, Amaury, Robert, Grégoire, Ravaud, Alain, Domblides, Charlotte

“…: Urothelial carcinoma (UC) has a poor prognosis, with the only standard first-line metastatic treatment being platinum-based chemotherapy. Until 2018, there…”
Get more information

How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma by Larroquette, Mathieu, Lefort, Félix, Domblides, Charlotte, Héraudet, Luc, Robert, Grégoire, Ravaud, Alain, Gross-Goupil, Marine

“…In the past decade, the therapeutic arsenal for metastatic bladder cancer has expanded considerably, with the development of immune checkpoint inhibitors…”
Get full text

Dramatic response after anti PD1 treatment failure in a squamous cell carcinoma of the maxillary sinus by Larroquette, Mathieu, Domblides, Charlotte, Cousin, Sophie, De Gabory, Ludovic, Dupin, Charles, Ravaud, Alain, Daste, Amaury

“…•Response with salvage chemotherapy was descript for head and neck carcinoma.•Few data concerning sinus cancer was noted.•We descripted a dramatic response…”
Get full text

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies by Larroquette, Mathieu, Guegan, Jean-Philippe, Besse, Benjamin, Cousin, Sophie, Brunet, Maxime, Le Moulec, Sylvestre, Le Loarer, François, Rey, Christophe, Soria, Jean-Charles, Barlesi, Fabrice, Bessede, Alban, Scoazec, Jean-Yves, Soubeyran, Isabelle, Italiano, Antoine

“…Tumor-associated macrophages (TAMs) having immunosuppressive properties are one of the most abundant immune cells in the tumor microenvironment (TME)…”
Get full text

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade by Larroquette, Mathieu, Lefort, Félix, Heraudet, Luc, Bernhard, Jean-Christophe, Ravaud, Alain, Domblides, Charlotte, Gross-Goupil, Marine

“…Clear cell renal cell carcinoma (RCC) oncogenesis is mainly driven by gene inactivation, leading to overexpression of vascular endothelial growth factor…”
Get full text

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study by Ladouceur, Alexandra, Barnetche, Thomas, Prey, Sorilla, Dutriaux, Caroline, Gerard, Émilie, Pham-Ledard, Anne, Beylot-Barry, Marie, Zysman, Maeva, Veillon, Rémi, Domblides, Charlotte, Daste, Amaury, Gross-Goupil, Marine, Sionneau, Baptiste, Lefort, Felix, Mathieu, Larroquette, Richez, Christophe, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Kostine, Marie

“…•Immune checkpoint inhibitors can safely be continued in most patients developing immune checkpoint inhibitors-induced inflammatory arthritis.•Immune…”
Get full text

KS01.6.A UCPVAX-GLIO: A PHASE II TRIAL EVALUATING THE IMMUNOGENICITY AND EFFICACY OF AN ANTI-TELOMERASE VACCINE IN PATIENTS WITH NEWLY DIAGNOSED GBM by Carpentier, A F, Verlut, C, Ghiringhelli, F, Bronnimann, C, Ursu, R, Fumet, J, Gherga, E, Lefort, F, Belin, C, Vernerey, D, Mathieu Larroquette, M, Hervieu, A, Laheurte, C, Meurisse, A, Jacquin, M, Malfroy, M, Kroemer, M, Clairet, A, Fagnoni-Legat, C, Lehmann-Che, J, Boullerot, L, Cuzzubbo, s, Adotevi, O

“…Abstract BACKGROUND The Telomerase Reverse Transcriptase (TERT) is activated in 85%-90% of cancers, and glioblastomas (GBM) harbor the highest incidence of…”
Get full text

Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice by Lefort, Félix, Rhanine, Yasmine, Larroquette, Mathieu, Domblides, Charlotte, Heraudet, Luc, Sionneau, Baptiste, Lambert, Simon, Lasserre, Matthieu, Robert, Grégoire, Ravaud, Alain, Gross-Goupil, Marine

“…Upper tract urothelial carcinoma (UTUC) is a rare disease included, along with the much more frequent urothelial bladder cancer (BUC), in the family of…”
Get full text

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option? by Granet-Vaissiere, Estelle, Lefort, Félix, Domblides, Charlotte, Larroquette, Mathieu, Ravaud, Alain, Bernhard, Jean-Christophe, Gross-Goupil, Marine

“…Over the past decade, major advances have been made in the treatment of advanced and metastatic renal cell carcinomas, specifically clear cell carcinomas. For…”
Get full text

FGF amplification an important targeted for head and neck cancer patient? A case report of a patient with FGF amplification treated with erdafitinib by Gibson, Nyere, Larroquette, Mathieu, Domblides, Charlotte, Lefort, Felix, Daste, Amaury

Get full text

Atypical presentation of a central nervous system aspergillosis in a peripheral T cell lymphoma patient by Larroquette, Mathieu, Issa, Nahéma, Gabriel, Frédéric, Camou, Fabrice

Get full text